News & Updates
Filter by Specialty:
Gut dysbiosis evident in patients with prodromal PD and their first-degree relatives
A cross-sectional study from the Chinese University of Hong Kong suggests that Parkinson’s disease (PD)–like gut dysbiosis occurs at preclinical prodromal stages of PD, in patients with video-polysomnography (v-PSG)–confirmed REM sleep behavior disorder (RBD) and even in their younger first-degree relatives (RBD-FDR).
Gut dysbiosis evident in patients with prodromal PD and their first-degree relatives
10 May 2023
Intranasal zavegepant offers rapid pain relief in patients with migraine
Treatment with zavegepant nasal spray provides pain and symptom relief in patients with migraine, according to a recent US study presented at AAN 2023.
Intranasal zavegepant offers rapid pain relief in patients with migraine
10 May 2023
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
09 May 2023
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.